Moneycontrol PRO
HomeNewsBusinessMarketsAkums Drugs inks licensing pact with Canadian firm

Akums Drugs inks licensing pact with Canadian firm

Shares of Akums Akums Drugs and Pharmaceuticals were trading 4.31 per cent up at Rs 919 apiece on BSE.

October 16, 2024 / 14:04 IST
Akums Drugs inks licensing pact with Canadian firm

Akums Drugs inks licensing pact with Canadian firm

Akums Drugs and Pharmaceuticals on Wednesday said it has inked a licensing pact with Canada-based Triple Hair Inc.

As per the terms of the agreement, the company has been granted exclusive rights to further develop and market the products recently innovated by Triple Hair Inc, in India, Akums Drugs and Pharmaceuticals said in a regulatory filing.

The company will undertake this development and commercialisation after obtaining the necessary regulatory approvals or requisite licenses in India, it added.

"The agreement grants the company exclusive right to use Triple Hair's intellectual property rights (patent) solely to carry out the studies and perform the services as stipulated in the agreement," the company said.

Further, the company will manage the commercial strategy to promote and offer Triple Hair's patented products to its own marketing partners and clients within the Indian market exclusively, it added.

Shares of Akums Akums Drugs and Pharmaceuticals were trading 4.31 per cent up at Rs 919 apiece on BSE.

PTI
first published: Oct 16, 2024 02:04 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347